Danish Biotech Weekly – Week 24

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, several companies reported positive results from trials including Initiator Pharma, Curasight and Fluoguide. Fluoguide only rose by 4% while Curasight fell by 1%. Their week performance following the announcements can be explained by the companies’ already strong year-to-date performance.

7 of the 20 listed, Danish biotech companies have published news the past week. 11 of the 20 companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Saniona is now the best performing stock this year.

Company news the past week

Ascendis Pharma

Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany (Link)

Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Link)


No news the past week


No news the past week

CS Medica

No news the past week


Curasight A/S reports positive preclinical results with uTREAT[®] in aggressive brain cancer (glioblastoma) (Link)

Evaxion Biotech

No news the past week


No news the past week


FluoGuide announces positive topline results from phase IIa trial of FG001 in lung cancer (Link)


Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 (Link)

Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (Link)


Gubra announces updates to its pipeline. Internally developed brain-accessible orexin peptides for the treatment of narcolepsy, now ready for partnering (Link)

Initiator Pharma

Initiator Pharma reports dose-dependent significant efficacy of IP2018 in the placebo-controlled Phase IIa clinical trial of Erectile Dysfunction (Link)

IO Biotech

No news the past week

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week


No news the past week

Zealand Pharma

Zealand Pharma to Participate in Upcoming Healthcare Conferences (Link)

Y-mAbs Therapeutics

No news the past week


No news the past week



The majority of the Danish Biotech stocks delivered a negative share price performance last week. The average return was however positive with 2.4%. Initiator Pharma rose 35% after they reported positive phase IIb studies with IP2018 against erectile dysfunction. Fluoguide rose just 4% after positive phase 2 results from its lead candidate FG001, which can make cancer cells luminescent. However, the explanation may be that the stock is already up 134% year-to-date. Curasight A/S, Fluoguide A/S and Saniona AB have been the best performing stocks year-to-date after soaring 134-154% after among other things partnerships and positive recommendations paving the way for approvals.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.